JB Chemicals & Pharmaceuticals Limited — Q4 FY26 earnings call

Call held 12 May 2026

Management summary

J.B. Chemicals & Pharmaceuticals reported a challenging Q4 FY26 with a 5% revenue de-growth to INR 904 crores, attributed to an operational reset and discontinuation of low-margin trade generics. Despite this, adjusted EBITDA remained flat at INR 241 crores, and margins improved significantly. The India branded business showed robust growth, while international formulations and CDMO faced headwinds. The merger with Torrent Pharma is nearing completion, with management anticipating normalization and synergy realization from Q1 FY27 onwards.

Highlights

  • Adjusted EBITDA margin improved by 2% to 27% in Q4 FY26 compared to 25% in the previous year.

  • Gross margin improved to 70% in Q4 FY26 from 66% in the corresponding quarter of the previous year.

  • India branded business grew 8% in Q4 FY26 and 11% for FY26, outperforming the IPM growth of 10%.

  • Chronic business grew 19% in FY26 versus the industry growth of 14%.

  • Net cash position stood at INR 1,200 crores as of FY26.

Concerns

  • Revenue registered a de-growth of 5% to INR 904 crores in Q4 FY26 due to an operational reset.

  • International formulations business reported a de-growth of 9% to INR 259 crores in Q4 FY26.

  • CDMO business revenues declined by 22% in Q4 FY26 due to a high base in the corresponding quarter of the previous year.

  • One-offs including non-cash ESOP charges amounted to INR 40 crores in Q4 FY26.

  • Container shipment constraints and the West Asia crisis negatively impacted international business.

Key financials

  1. Revenue ₹904 Cr -5%YoY
  2. Adjusted EBITDA ₹241 Cr 0%YoY
  3. Gross Margin 70%
  4. Adjusted EBITDA Margin 27%
  5. Reported PAT ₹101 Cr
  6. Adjusted PAT ₹150 Cr

What they filed

Q4 FY26: revenue down 7.2%, net profit down 35.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue952 956 914 901 1,040 +9%1,023 +7%991 +8%836 −7%
EBITDA273 268 245 231 293 +7%298 +11%270 +10%195 −16%
Net profit173 173 156 150 198 +14%200 +16%179 +15%97 −35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of FY26 Revenue
₹4,060 Cr Total
  • India Business ₹2,461 Cr 60.6%
  • International Formulations ₹1,154 Cr 28.4%
  • CDMO Business ₹445 Cr 11.0%

Capital allocation

high confidence
  • Dividend ₹9.3/share (final)
    The Board of Directors have recommended a final dividend of INR9.3 per equity share of INR1 each for the year FY'26.
  • M&A Torrent Pharma Merger · Pending regulatory · Consideration ₹[object Object] (undisclosed)

    Integration with parent entity for synergies and operational efficiency.

    Operational reset in Q4 FY26, normalization expected from Q1 FY27.

    On the merger process, we have received the requisite shareholder approvals for the merger of JB Pharma with Torrent and we are in the last stage of the process now. So, I think we're at the last phase of the merger process and the hearing date which we've got is in the second week of June. So, let's see. So, I think it should be one to two months' time max for the merger should get effective I would say.
  • Liquidity Cash ₹1,200 Cr Net cash position for JB as of FY26.
    Just one book-keeping question. Can you call out the net cash number for JB as of FY26? Rahul, it is around INR1,200 cr.

Guidance & targets

Revenue

  • India Business Growth Revenue · next couple of quarters · Medium confidence double-digit or low teens
    So, India business, double-digit growth or low teens growth would take maybe a couple of quarters.

    — Aman Mehta

  • International Business Growth Revenue · Q1, more likely Q2 · Medium confidence single-digit
    International business single-digit growth should continue potentially from Q1 but more likely from Q2.

    — Aman Mehta

  • CDMO Business Momentum Revenue · 12-month basis · Medium confidence positive momentum
    So on a 12-month basis, I would say that it would be having a positive momentum.

    — Sanjay Gupta

  • Impact of Trade Generics Discontinuation Revenue · next three quarters · High confidence continue
    Yes, that would be fair to say or assume. The exact number maybe Kaushal can help pull out but the trade generics contribution to the overall India top line is about 7% to 8% or was about 7% to 8% till Q3, which we've taken steps to significantly rationalize. So obviously because of that the overall India business growth would remain a bit lower than the branded business growth.

    — Aman Mehta

Other

  • Merger Effectiveness Other · one to two months · High confidence effective
    So, I think it should be one to two months' time max for the merger should get effective I would say.

    — Sudhir Menon

What to watch in Q1 FY27

India Business Growth Normalization

next couple of quarters (from Q1 FY27)
Current 2% YoY in Q4 FY26 (overall), 8% (branded)
Target double-digit or low teens growth

Why it matters

Indicates the success of integration steps and recovery from trade generics discontinuation, crucial for overall company growth.

So, India business, double-digit growth or low teens growth would take maybe a couple of quarters.

Risks & concerns

  • Operational reset impacting performance

    medium

    Q4 FY26 was a period of operational reset, which temporarily impacted performance, but normalization is expected from Q1 FY27.

    Management acknowledged

  • Discontinuation of low-margin trade generics business

    medium

    This strategic decision led to sequential slowdown in India business growth and will continue to impact overall India growth for the next three quarters.

    Management acknowledged

  • Container shipment constraints and West Asia crisis

    medium

    These external factors negatively impacted international formulations business, particularly in the Middle East and Asia.

    Management acknowledged

  • CDMO execution challenges

    medium

    Challenges in the CDMO segment are primarily on the development side due to a lean organization, requiring additional resources for faster project execution.

    Management acknowledged

Q&A highlights

6 direct, 1 evasive
Normalization of growth post operational reset Direct
So, India business, double-digit growth or low teens growth would take maybe a couple of quarters. We're already seeing all the positive signs. International business single-digit growth should continue potentially from Q1 but more likely from Q2.

Clarifies management's expectation for recovery timelines in both India and International businesses after the Q4 operational reset.

Asked by Neha from Bank of America

Sustainability of gross margin improvement Partial
So Neha, I think there has been an improvement of 4% in this quarter, partially because of the trade generic reset which we've done and partially because of product mix. So I think for us to give some guidance on where it will settle for the full year, I would like to wait for one more quarter. First quarter will be indicative of where we are headed for.

Indicates that while gross margin improved due to strategic changes, management needs another quarter to confirm the new sustainable base.

Asked by Neha from Bank of America

Timeline for merger completion with Torrent Pharma Direct
So, I think we're at the last phase of the merger process and the hearing date which we've got is in the second week of June. So, let's see. So, I think it should be one to two months' time max for the merger should get effective I would say.

Provides a clear, albeit approximate, timeline for the finalization of the significant merger event.

Asked by Devansh Jain from Neo Wealth Management

Impact of trade generics discontinuation on India business growth Direct
Yes, that would be fair to say or assume. The exact number maybe Kaushal can help pull out but the trade generics contribution to the overall India top line is about 7% to 8% or was about 7% to 8% till Q3, which we've taken steps to significantly rationalize. So obviously because of that the overall India business growth would remain a bit lower than the branded business growth.

Quantifies the contribution of the discontinued trade generics business and confirms its negative impact on overall India growth for the near term.

Asked by Rahul Jeewani from IIFL Securities

Positive and negative surprises post operational control by Torrent Direct
I think the positive surprises definitely would be that the brands in the India business in particular continue to give us confidence that, you know, these are such widely established and recognized brands and familiarity is so high that in a merged entity it would certainly be possible to accelerate the growth further. I think that was the thesis going in and we remain confident of that. On the negative I think probably integration we had to take the step that we did in Q4.

Highlights the strategic rationale for the acquisition (strong brands) and acknowledges the short-term operational impact of integration steps.

Asked by Rahul Jeewani from IIFL Securities

Outlook and challenges for the CDMO business Direct
So, I mean the challenges are more in the development side because JB had a very lean development organization, product development and so we need to bring additional resources to product development so that the projects can be kind of executed faster. In terms of just underlying growth drivers, besides timely execution of deals that are already signed, we have, you know, the top companies in the world in the customer mix.

Identifies specific bottlenecks in the CDMO segment related to development resources and execution, despite having strong customer relationships and new contracts.

Asked by Alok Dalal from Jefferies India

Strategies to tap synergies in the domestic market Direct
In terms of revenue, I think as you mentioned, definitely there is a lot of complementarity in the portfolio where coverage can be enhanced significantly for JB brands and brand equity can kind of be interchanged in products where either of the entity has a stronger presence, whether Torrent or JB. ... Second would be procurement synergies which will start playing out now... Third would be in the corporate overhead costs which things like distribution network optimization which has already been done and should start taking effect from April in terms of visibility in margin improvement.

Outlines the multi-faceted approach to synergy realization, covering portfolio complementarity, procurement, and corporate overheads, with specific timelines for impact.

Asked by Bino Pathiparampil from Elara Capital

Potential reduction in combined sales force post-merger Evasive
We would not want to comment on that at this stage. Maybe from Q1 onwards we can give a more color on the number of reps and so on.

Management defers comment on a sensitive integration aspect (sales force rationalization), indicating it's a future consideration.

Asked by Bino Pathiparampil from Elara Capital

2 min read 5 chapters

Detailed narrative

Q4 FY26 Performance Overview and Operational Reset

J.B. Chemicals & Pharmaceuticals experienced an operational reset in Q4 FY26, leading to a 5% de-growth in revenue to INR 904 crores. Despite this, adjusted EBITDA remained flat at INR 241 crores, and the adjusted EBITDA margin improved by 2% to 27% compared to the previous year. Gross margin also saw a significant improvement, rising to 70% from 66%, primarily due to the discontinuation of low-margin trade generics and a favorable product mix. Reported net profit after tax was INR 101 crores, which adjusted for INR 40 crores of one-offs (including non-cash ESOP charges) stood at INR 150 crores.

India Business Growth and Strategic Adjustments

The India business grew by 2% year-on-year to INR 526 crores in Q4 FY26. However, the branded business within India demonstrated stronger performance, growing 8% for the quarter. For the full fiscal year FY26, the India business grew 9% to INR 2,461 crores, with the branded segment growing 11%. This outperformance is evident in IQVIA MAT March'26 data, showing India business growth at 11% versus IPM growth of 10%, and chronic business growth at 19% versus industry growth of 14%. The sequential slowdown was attributed to the discontinuation of the low-margin trade generics business, which contributed 7-8% to the India top line until Q3.

International Business and CDMO Segment Challenges

The International formulations business faced headwinds in Q4 FY26, reporting a de-growth of 9% to INR 259 crores. For the full year FY26, international formulations revenue grew 2% to INR 1,154 crores. This decline was linked to container shipment constraints and the West Asia crisis. The CDMO business also saw a 22% decline in Q4 revenues due to a high base in the prior year, though it remained flat at INR 445 crores for the full FY26. Management expects positive momentum for CDMO over the next 12 months but acknowledges challenges in development-side execution due to a lean organizational structure.

Integration with Torrent Pharma and Synergy Realization

The merger process with Torrent Pharma is in its final stages, with shareholder approvals received and a hearing scheduled for the second week of June, expecting effectiveness within one to two months. Integration steps in Q4 FY26 included optimizing the distribution network, discontinuing low-margin trade generics, and aligning trade and sales practices. Management anticipates gradual recovery to original growth trajectories, with India business reaching double-digit/low teens growth in a couple of quarters and international business seeing single-digit growth from Q1/Q2 FY27. Synergies are expected from portfolio complementarity, procurement, and corporate overhead optimization, with visibility in margin improvement from April 2026.

Capital Allocation and Shareholder Returns

The Board of Directors recommended a final dividend of INR 9.3 per equity share for FY26. The company maintained a healthy liquidity position, with a net cash balance of approximately INR 1,200 crores as of FY26. Management did not discuss specific capital expenditure plans or debt management activities during the call, focusing instead on the ongoing integration and operational adjustments.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls